Skip to content

Study · Measured the body's own peptide · 1991

2 results

Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues.

Pradelles P, Frobert Y, Créminon C, Ivonine H, Frindel E

FEBS letters1 Sept 1991Cited by 64 (Europe PMC)

PMID1915845 (opens in a new tab)DOI10.1016/0014-5793(91)81062-d (opens in a new tab)PepBankPUB-01915845
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelEx vivo tissueMechanism

    Enzyme immunoassays combined with HPLC showed that the body's own thymosin beta‑4 is ubiquitous in mouse tissue extracts.

    In plain wordsIn mouse tissue samples, the body's own thymosin beta‑4 was found throughout the tissues tested.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin beta 4 distribution in mouse tissues
    Study

    mousen: not reported in source

    Mouse tissue extracts
    Outcome group
    Endogenous peptide levels · Whole body

    Source sentences

    Summary
    The combination of EIAs with different HPLC procedures validated these methods and clearly demonstrated the ubiquity of these peptides in mouse tissues.
    1 context sentence
    Summary · context
    Using this assay and a previously described EIA for AcSDKP, a negative regulator of pluripotent haematopoietic stem cell proliferation, the levels of these two peptides were determined in mouse tissue extracts.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueOther

    A competitive enzyme immunoassay with acetylcholinesterase as tracer was developed to measure thymosin beta‑4.

    In plain wordsResearchers built a lab test to measure thymosin beta‑4 in tissue samples.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableCompetitive enzyme immunoassay for thymosin beta 4
    Study

    mousen: not reported in source

    Mouse tissue extracts
    Outcome group
    Endogenous peptide levels · Whole body

    Source sentences

    Summary
    A competitive enzyme immunoassay using acetylcholinesterase as tracer for thymosin beta 4, has been developed.
    1 context sentence
    Summary · context
    Using this assay and a previously described EIA for AcSDKP, a negative regulator of pluripotent haematopoietic stem cell proliferation, the levels of these two peptides were determined in mouse tissue extracts.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.